Alkem Laboratories, a leading Indian pharmaceutical company, announced its financial results for the fourth quarter (Q4FY24) and the full fiscal year 2024 (FY24).
Q4FY24 Financial Highlights:
Total Revenue from Operations: ₹29,358 million (1.1% YoY growth)
India sales: ₹19,724 million (-1.9% YoY)
International sales: ₹9,096 million (6.1% YoY growth)
EBITDA: ₹4,020 million (13.7% EBITDA margin vs. 12.2% in Q4FY23)
EBITDA Growth: 13.8% YoY increase
Profit Before Tax (PBT) before exceptional items: ₹3,799 million (20.7% growth compared to Q4FY23)
Net Profit (after Minority Interest): ₹2,936 million (313.6% YoY growth)
Note: Q4FY23 PAT was impacted due to derecognition of deferred tax. Adjusted for this, PAT growth for Q4FY24 would have been 54%.
R&D expenses: ₹491 million (1.7% of sales)
FY24 Financial Highlights:
Total Revenue from Operations: ₹126,676 million (9.2% YoY growth)
India sales: ₹84,337 million (5.4% YoY growth)
International sales: ₹40,024 million (16.4% YoY growth)
EBITDA: ₹22,455 million (17.7% EBITDA margin vs. 13.9% in FY23)
EBITDA Growth: 39.5% YoY increase
Key Takeaways:
Steady Growth: Alkem Laboratories demonstrated consistent growth in both revenue and profitability in FY24.
Strong International Performance: International sales were a major growth driver, reflecting the company's expanding global presence.
Improved Profitability: EBITDA and PAT margins improved significantly, indicating efficient operations and cost management.
R&D Investment: The company continued to invest in research and development, contributing to its future growth prospects.
For further information and analysis, you can refer to the following resources:
ICICI Direct Analysis: https://www.icicidirect.com/research/equity/rapid-results/alkem-laboratories-ltd
5paisa Share Price: https://www.5paisa.com/stocks/alkem-share-price
Comments